PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933325
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933325
Cardiac Troponin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of cardiac troponin Market
The global cardiac troponin market is witnessing robust growth, driven by the rising prevalence of cardiovascular diseases, growing adoption of advanced diagnostic technologies, and increasing emphasis on early detection of myocardial injury. Cardiac troponin is a highly specific biomarker used for the diagnosis of myocardial infarction (MI) and acute coronary syndromes (ACS). Its ability to detect even minimal cardiac muscle damage has made it an indispensable tool in emergency and critical care settings.
In 2025, the global cardiac troponin market was valued at USD 3.50 billion. The market is projected to grow to USD 3.78 billion in 2026 and further expand to USD 7.17 billion by 2034, registering a CAGR of 8.30% from 2026 to 2034. This steady expansion reflects the increasing burden of heart-related disorders worldwide and the continuous evolution of high-sensitivity testing solutions.
Market Drivers
The growing prevalence of cardiovascular diseases (CVDs) remains the primary driver of the cardiac troponin market. According to the Centers for Disease Control and Prevention (CDC), in the U.S., one person experiences a heart attack every 40 seconds, highlighting the urgent need for rapid and accurate diagnostic tools. Elevated troponin levels are directly linked to myocardial injury, making troponin testing a standard protocol for diagnosing heart attacks and monitoring disease progression.
Additionally, the aging global population is significantly contributing to market growth. Older adults are more susceptible to chronic conditions such as hypertension, coronary artery disease, and heart failure. The increasing geriatric population is driving higher hospitalization rates and demand for cardiac biomarker testing, including troponin assays.
Market Trends
A key trend shaping the market is the increasing adoption of high-sensitivity and point-of-care (POC) troponin tests. These advanced tests enable faster turnaround times and improved diagnostic accuracy, particularly in emergency departments. High-sensitivity assays can detect very low levels of troponin, allowing early identification of myocardial infarction and differentiation between acute and chronic cardiac conditions.
Technological advancements and regulatory approvals are further accelerating adoption. For instance, the U.S. FDA's approval of high-sensitivity troponin assays has strengthened their clinical acceptance and expanded their use in routine cardiac diagnostics.
Restraining Factors
Despite strong growth prospects, the market faces challenges related to the limited sensitivity of conventional troponin assays. Traditional tests may fail to detect low troponin concentrations during the early hours following myocardial injury, potentially delaying diagnosis. This limitation underscores the need for advanced high-sensitivity assays but also restricts adoption in regions with limited access to newer technologies.
Segmentation Analysis
By type, the market is segmented into troponin I and troponin T. The troponin I segment dominated the market in 2026, accounting for 73.32% of the global share, due to its high cardiac specificity and widespread use in MI diagnosis. The troponin T segment is expected to witness steady growth, supported by increasing regulatory approvals and its expanding role in heart failure screening.
Based on setting, the market is divided into laboratory testing and point-of-care testing. Laboratory testing held the largest share in 2026 at 73.68%, driven by higher accuracy and detailed quantitative analysis. However, the POC testing segment is expected to grow at a faster rate due to increasing use in emergency and resource-limited settings.
By end user, hospitals and clinics dominated the market with a 63.44% share in 2026, owing to high patient admissions and extensive use of troponin tests in emergency cardiac care.
Regional Insights
North America dominated the global cardiac troponin market in 2025, accounting for 41.15% share and generating USD 1.44 billion in revenue. The region benefits from advanced healthcare infrastructure, favorable reimbursement policies, and high adoption of high-sensitivity assays. The U.S. market is projected to reach USD 1.40 billion by 2026.
Europe held the second-largest share, supported by widespread adoption of CE-marked high-sensitivity assays and strong regulatory frameworks. Asia Pacific is anticipated to be the fastest-growing region due to rising cardiovascular disease prevalence, expanding diagnostic infrastructure, and increasing awareness. By 2026, China, Japan, and India are projected to reach USD 0.28 billion, USD 0.19 billion, and USD 0.14 billion, respectively.
Competitive Landscape
The cardiac troponin market is moderately competitive, with key players focusing on product innovation, regulatory approvals, and strategic collaborations. F. Hoffmann-La Roche Ltd. leads the market due to its strong high-sensitivity troponin portfolio. Other prominent players include Abbott, Siemens Healthineers, bioMerieux, Beckman Coulter, and QuidelOrtho.
Conclusion
The global cardiac troponin market is poised for strong and sustained growth over the forecast period, driven by the rising burden of cardiovascular diseases, expanding geriatric population, and rapid adoption of high-sensitivity and point-of-care diagnostic technologies. From a market size of USD 3.50 billion in 2025, the industry is expected to reach USD 7.17 billion by 2034. While limitations of conventional assays remain a challenge, continuous technological advancements, increasing regulatory approvals, and growing emphasis on early cardiac diagnosis are expected to unlock significant growth opportunities. Overall, cardiac troponin testing will remain a cornerstone of modern cardiovascular diagnostics worldwide.
Segmentation
By Type
- Troponin T
- Troponin I
By Setting
- Laboratory Testing
- Point-of-Care (POC) Testing
By Indication
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Others
By End User
- Hospitals & Clinics
- Diagnostic Laboratories
- Homecare Settings & Others
By Region
- North America ( By Type, By Setting, By Indication, By End User, By Country)
- U.S.
- Canada
- Europe ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
- Latin America ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Key Cardiovascular Diseases, By Key Countries/Regions, 2024/2025
- 4.2. Technological Advancements in Cardiac Troponin Testing
- 4.3. New Product Launches. By Key Players
- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships etc.)
- 4.5. Impact of COVID-19 on the Market
5. Global Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Troponin T
- 5.1.2. Troponin I
- 5.2. Market Analysis, Insights and Forecast - By Setting
- 5.2.1. Laboratory Testing
- 5.2.2. Point-of-Care (POC) Testing
- 5.3. Market Analysis, Insights and Forecast - By Indication
- 5.3.1. Myocardial Infarction
- 5.3.2. Congestive Heart Failure
- 5.3.3. Acute Coronary Syndrome
- 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast - By End-User
- 5.4.1. Hospitals & Clinics
- 5.4.2. Diagnostic Laboratories
- 5.4.3. Homecare Settings & Others
- 5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Troponin T
- 6.1.2. Troponin I
- 6.2. Market Analysis, Insights and Forecast - By Setting
- 6.2.1. Laboratory Testing
- 6.2.2. Point-of-Care (POC) Testing
- 6.3. Market Analysis, Insights and Forecast - By Indication
- 6.3.1. Myocardial Infarction
- 6.3.2. Congestive Heart Failure
- 6.3.3. Acute Coronary Syndrome
- 6.3.4. Others
- 6.4. Market Analysis, Insights and Forecast - By End-User
- 6.4.1. Hospitals & Clinics
- 6.4.2. Diagnostic Laboratories
- 6.4.3. Homecare Settings & Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Troponin T
- 7.1.2. Troponin I
- 7.2. Market Analysis, Insights and Forecast - By Setting
- 7.2.1. Laboratory Testing
- 7.2.2. Point-of-Care (POC) Testing
- 7.3. Market Analysis, Insights and Forecast - By Indication
- 7.3.1. Myocardial Infarction
- 7.3.2. Congestive Heart Failure
- 7.3.3. Acute Coronary Syndrome
- 7.3.4. Others
- 7.4. Market Analysis, Insights and Forecast - By End-User
- 7.4.1. Hospitals & Clinics
- 7.4.2. Diagnostic Laboratories
- 7.4.3. Homecare Settings & Others
- 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Rest of Europe
8. Asia Pacific Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Troponin T
- 8.1.2. Troponin I
- 8.2. Market Analysis, Insights and Forecast - By Setting
- 8.2.1. Laboratory Testing
- 8.2.2. Point-of-Care (POC) Testing
- 8.3. Market Analysis, Insights and Forecast - By Indication
- 8.3.1. Myocardial Infarction
- 8.3.2. Congestive Heart Failure
- 8.3.3. Acute Coronary Syndrome
- 8.3.4. Others
- 8.4. Market Analysis, Insights and Forecast - By End-User
- 8.4.1. Hospitals & Clinics
- 8.4.2. Diagnostic Laboratories
- 8.4.3. Homecare Settings & Others
- 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. Rest of Asia Pacific
9. Latin America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Troponin T
- 9.1.2. Troponin I
- 9.2. Market Analysis, Insights and Forecast - By Setting
- 9.2.1. Laboratory Testing
- 9.2.2. Point-of-Care (POC) Testing
- 9.3. Market Analysis, Insights and Forecast - By Indication
- 9.3.1. Myocardial Infarction
- 9.3.2. Congestive Heart Failure
- 9.3.3. Acute Coronary Syndrome
- 9.3.4. Others
- 9.4. Market Analysis, Insights and Forecast - By End-User
- 9.4.1. Hospitals & Clinics
- 9.4.2. Diagnostic Laboratories
- 9.4.3. Homecare Settings & Others
- 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Troponin T
- 10.1.2. Troponin I
- 10.2. Market Analysis, Insights and Forecast - By Setting
- 10.2.1. Laboratory Testing
- 10.2.2. Point-of-Care (POC) Testing
- 10.3. Market Analysis, Insights and Forecast - By Indication
- 10.3.1. Myocardial Infarction
- 10.3.2. Congestive Heart Failure
- 10.3.3. Acute Coronary Syndrome
- 10.3.4. Others
- 10.4. Market Analysis, Insights and Forecast - By End-User
- 10.4.1. Hospitals & Clinics
- 10.4.2. Diagnostic Laboratories
- 10.4.3. Homecare Settings & Others
- 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. F. Hoffmann-La Roche Ltd.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. financials (Based on Availability)
- 11.2.2. bioMerieux SA
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. financials (Based on Availability)
- 11.2.3. Abbott
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. financials (Based on Availability)
- 11.2.4. Siemens Healthineers AG
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. financials (Based on Availability)
- 11.2.5. Eurolyser Diagnostica GmbH
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. financials (Based on Availability)
- 11.2.6. QuidelOrtho (Quidel Corporation)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. financials (Based on Availability)
- 11.2.7. PerkinElmer Inc.
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. financials (Based on Availability)
- 11.2.8. Beckman Coulter, Inc. (Danaher)
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. financials (Based on Availability)
- 11.2.9. RESPONSE BIOMEDICAL
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. financials (Based on Availability)
- 11.2.10. LifeSign LLC.
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. financials (Based on Availability)
- 11.2.1. F. Hoffmann-La Roche Ltd.
List of Tables
- Table 1: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 2: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
- Table 3: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 4: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 5: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 6: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 7: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
- Table 8: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 9: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 10: North America Cardiac Troponin Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 11: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 12: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
- Table 13: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 14: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 15: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 16: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 17: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
- Table 18: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 19: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 20: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 22: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
- Table 23: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 24: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 25: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 26: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 27: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
- Table 28: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
- Table 29: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
- Table 30: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Cardiac Troponin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Cardiac Troponin Market Value Share (%), By Type, 2025 & 2034
- Figure 3: Global Cardiac Troponin Market Value Share (%), by Setting, 2025 & 2034
- Figure 4: Global Cardiac Troponin Market Value Share (%), by Indication, 2025 & 2034
- Figure 5: Global Cardiac Troponin Market Value Share (%), by End-User, 2025 & 2034
- Figure 6: Global Cardiac Troponin Market Value (USD billion), by Region, 2025 & 2034
- Figure 7: North America Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
- Figure 8: North America Cardiac Troponin Market Value Share (%), By Type, 2025
- Figure 9: North America Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
- Figure 10: North America Cardiac Troponin Market Value Share (%), by Setting, 2025
- Figure 11: North America Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
- Figure 12: North America Cardiac Troponin Market Value Share (%), by Indication, 2025
- Figure 13: North America Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
- Figure 14: North America Cardiac Troponin Market Value Share (%), by End-User, 2025
- Figure 15: North America Cardiac Troponin Market Value (USD billion), By Country, 2025 & 2034
- Figure 16: North America Cardiac Troponin Market Value Share (%), By Country, 2025
- Figure 17: Europe Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
- Figure 18: Europe Cardiac Troponin Market Value Share (%), By Type, 2025
- Figure 19: Europe Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
- Figure 20: Europe Cardiac Troponin Market Value Share (%), by Setting, 2025
- Figure 21: Europe Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
- Figure 22: Europe Cardiac Troponin Market Value Share (%), by Indication, 2025
- Figure 23: Europe Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
- Figure 24: Europe Cardiac Troponin Market Value Share (%), by End-User, 2025
- Figure 25: Europe Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 26: Europe Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
- Figure 27: Asia Pacific Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
- Figure 28: Asia Pacific Cardiac Troponin Market Value Share (%), By Type, 2025
- Figure 29: Asia Pacific Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
- Figure 30: Asia Pacific Cardiac Troponin Market Value Share (%), by Setting, 2025
- Figure 31: Asia Pacific Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
- Figure 32: Asia Pacific Cardiac Troponin Market Value Share (%), by Indication, 2025
- Figure 33: Asia Pacific Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
- Figure 34: Asia Pacific Cardiac Troponin Market Value Share (%), by End-User, 2025
- Figure 35: Asia Pacific Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 36: Asia Pacific Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
- Figure 37: Latin America Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
- Figure 38: Latin America Cardiac Troponin Market Value Share (%), By Type, 2025
- Figure 39: Latin America Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
- Figure 40: Latin America Cardiac Troponin Market Value Share (%), by Setting, 2025
- Figure 41: Latin America Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
- Figure 42: Latin America Cardiac Troponin Market Value Share (%), by Indication, 2025
- Figure 43: Latin America Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
- Figure 44: Latin America Cardiac Troponin Market Value Share (%), by End-User, 2025
- Figure 45: Latin America Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 46: Latin America Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
- Figure 47: Middle East & Africa Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
- Figure 48: Middle East & Africa Cardiac Troponin Market Value Share (%), By Type, 2025
- Figure 49: Middle East & Africa Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
- Figure 50: Middle East & Africa Cardiac Troponin Market Value Share (%), by Setting, 2025
- Figure 51: Middle East & Africa Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
- Figure 52: Middle East & Africa Cardiac Troponin Market Value Share (%), by Indication, 2025
- Figure 53: Middle East & Africa Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
- Figure 54: Middle East & Africa Cardiac Troponin Market Value Share (%), by End-User, 2025
- Figure 55: Middle East & Africa Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034s
- Figure 56: Middle East & Africa Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
- Figure 57: Global Cardiac Troponin Market Share (%), By Company, 2025
